These compact, modular domains represent powerful entry points for engineering chaperone-based therapeutics to reestablish nuclear TDP-43 homeostasis in ALS/FTD and related TDP-43 proteinopathies. The gene discussed is TARDBP; the disease is proteostasis deficiencies.